Siteman Kids is the First Site of Multicenter CAR-T Trial for Autoimmune Diseases
Access to the novel immunotherapy — which “has the potential for cure” — is the latest offering by the national leader in pediatric hematology, oncology, and cell therapies. Siteman Kids at St. Louis Children’s Hospital, along with WashU Medicine in St. Louis, is the first site to test a novel immunotherapy drug for the […]
Promising Memory-Like NK Cell Therapy Spurs Trial Expansion Available Only at Siteman Kids at St. Louis Children’s Hospital and Siteman Cancer Center
ST. LOUIS — Oncologists at WashU Medicine in St. Louis are expanding an ongoing stem cell transplant study that previously enrolled only patients in remission. The study — shown to be safe and effective and aimed at preventing relapse — now also includes patients with refractory disease and those with two or more transplants. […]
More Than 30 Countries Now Participate in Siteman Kids’ Pediatric Neuro-Oncology Tumor Boards
Collaborative Approach Enhances Care for Children with Brain Tumors and NF Worldwide An international pediatric brain tumor board established by Mohamed Shebl Abdelbaki, MD, WashU Medicine pediatric oncologist and director of the Pediatric Neuro-Oncology Program at Siteman Kids at St. Louis Children’s Hospital, is rapidly becoming a collaborative, global force in efforts to better […]
Enrolling Now: ‘High Five’ Study Investigates Short-Term, High-Dose Radiation Therapy for High-Risk Prostate Cancer
A promising study evaluating the use of ultra-hypofractionation radiation therapy for the treatment of high-risk prostate cancer is underway at all six locations of Siteman Cancer Center, based at Barnes-Jewish Hospital and WashU Medicine. Called the “High Five” clinical trial, or NRG-GU-013, the phase III multicenter study will help determine whether five high-dose stereotactic body […]
Immunotherapy improves survival of patients with locally advanced head and neck cancer
Approved drug that revolutionized melanoma treatment may change standard of care for yet another cancer type Research presented at the annual meeting of the American Association for Cancer Research (AACR) in April provides the strongest clinical evidence to date that standard of care therapy could soon be updated for the treatment of resectable locally advanced […]